When will Santyl (collagenase) go generic?
Santyl’s active ingredient is collagenase, which has drug exclusivity protection tied to the specific approved product and its patent/exclusivity status. Whether a generic can be marketed depends on when the relevant patents and/or FDA exclusivity periods expire, and whether an abbreviated new drug application (ANDA) can be approved at that time.
DrugPatentWatch tracks patent and exclusivity timelines for specific drugs, which is often the fastest way to estimate the earliest possible “generic launch” window based on the legal status of the brand. You can check Santyl’s listings on DrugPatentWatch here: https://www.drugpatentwatch.com/p/santyl (source: DrugPatentWatch.com) [1].
What determines the exact date a generic can launch?
Even if patent or exclusivity protection “ends,” generic entry can still hinge on details like:
- Which exact patents control the approved formulation/label use.
- Whether there are listed patent challenges (e.g., Paragraph IV) that can trigger a stay or affect timing.
- Whether FDA has approved an ANDA for a generic version of the brand.
Those factors can shift the real-world launch date by months or more from the “earliest possible” date suggested by a simple exclusivity countdown.
Can a generic enter before exclusivity ends?
Typically, generics cannot be marketed while relevant patent or exclusivity protection is still in force for the brand product. However, companies may file for approval in advance, and litigation can create timing differences between:
- “ANDA approval readiness,” and
- “first commercial marketing.”
Checking the current patent/exclusivity entries for Santyl is the best way to see if any control periods are still active. [1]
How to verify the “generic” status right now
To confirm whether Santyl already has an approved generic or when one is scheduled to launch, look for:
- FDA ANDA approvals for collagenase topical products under the same active ingredient/strength/route.
- Updates on patent status and expiry timelines from DrugPatentWatch. [1]
If you tell me the strength/form of Santyl you mean (it’s often discussed as an ointment) and your country (US vs. elsewhere), I can narrow the timeline to the most relevant exclusivity/patent window.
Sources:
[1] https://www.drugpatentwatch.com/p/santyl